More than 18 billion antidepressant market has attracted a large number of domestic pharmaceutical companies to seize the beach!

【Pharmaceutical network industry dynamics】Depression is a common mental illness, with significant and lasting emotional depression as the main clinical feature, the number of depression patients in China is huge, about 100 million people
.

Antidepressants are currently one of the main means of treating depression, and the market size is showing a year-on-year growth trend
.

Consulting firm Sullivan predicts that the size of China's antidepressant market will reach 18.
41 billion yuan
in 2022.

In the past, China's antidepressant market was mainly occupied by the import of drugs by multinational pharmaceutical companies such as Lilly, and in recent years, with the rise of local pharmaceutical companies' research and development strength, this market has also attracted a large number of domestic pharmaceutical companies to actively layout
.

Since 2022, a large number of domestic pharmaceutical companies have received good news that antidepressant drugs have been approved for listing, including many large varieties
of more than 1 billion yuan.

These approved products will compete with the original research and other entrants on the track to grab the market cake
.

Paroxetine: ushering in the third entrant On September 21, Fuyuan Pharmaceutical issued an announcement that the company received the "Drug Registration Certificate" of Paroxetine hydrochloride enteric-coated extended-release tablets (specifications: according to C19H20FNO3 (1) 12.
5mg, (2) 25mg) issued by the State Food and Drug Administration, and approved the production of
the drug.

This time to obtain the "Drug Registration Certificate" is deemed to have passed the consistency evaluation
.

Paroxetine hydrochloride enteric-coated extended-release tablets were originally developed as GSK and were released
in the United States on February 16, 1999.

According to GlaxoSmithKline's 2021 annual report, global sales of the product are $152 million
.

In China, according to the website information of the State Food and Drug Administration, there are 3 manufacturers of paroxetine hydrochloride enteric-coated extended-release tablets that have been approved for listing in Chinese mainland,
including Fuyuan Pharmaceutical.

According to data from the Intranet, the total sales of paroxetine in the domestic medical market in 2021 will reach 586 million yuan, of which the total sales of paroxetine hydrochloride enteric-coated sustained release tablets will be 53.
95 million yuan
.

Venlafaxine: Increased to 5 companies in the evaluation In August, Poinsettia announced that its wholly-owned subsidiary Guangzhou Poinsettia Pharmaceutical's Wenlafaxine hydrochloride extended-release capsules (specification: 75mg) were approved for listing, which is regarded as passing the consistency evaluation of
generic drugs.

This product is used to treat depression (including depression with anxiety) and generalized anxiety disorders, and is the first-line treatment recommended by the guidelines for the diagnosis and treatment of depression and generalized anxiety disorder in many countries
.

As of the announcement date, 6 enterprises in the Wenlafaxin Hydrochloride Slow Release Court have production approvals, of which 5 domestic pharmaceutical companies have been evaluated
, including Hunan Dong Pharmaceutical, Beijing Fuyuan Pharmaceutical, and Guangzhou Poinsettia Pharmaceutical.

There are also 3 companies on the track that submit listing applications in the imitation of 4 categories, and are deemed to have been evaluated
after approval.

Venlafaxine hydrochloride extended-release capsules belong to the national medical insurance class A products, national basic drug species
.

According to data from the Intranet network, in 2021, the terminal sales of venlafaxine in China's urban public hospitals and counties will reach 1.
252 billion yuan
.

Duloxetine: Add another competitor On June 17, Yongtai Technology announced that the company's doloxetine hydrochloride enteric-coated capsules have obtained a drug registration certificate for the following indications: depression, generalized anxiety disorder and chronic musculoskeletal pain
.

Duloxetine hydrochloride enteric-coated capsules were developed by Eli Lilly and were released
in the United States in August 2004.

In China, duloxetine is a Class B variety
in the 2021 edition of the medical insurance catalog.

According to Intranet data, in 2021, the sales of duloxetine terminals in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) have exceeded 900 million yuan
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.